AdJane Biosciences Proposes Mucosal Booster for Respiratory Vaccines

AdJane Biosciences has introduced a new strategy for the development of next-generation respiratory vaccine franchises. The company's white paper details how its clinically validated Nm-nOMV platform could offer a proprietary mucosal component to existing intramuscular vaccination programs.

The company believes its technology can provide mucosal immunity, which is critical for combating respiratory illnesses. This approach targets pathogens at their entry points, potentially strengthening the body's defense mechanisms.

The Nm-nOMV platform has undergone clinical validation and is presented as compatible with current intramuscular vaccine regimens. The aim is to improve vaccine efficacy and broaden their protective scope.

With the publication of this white paper, AdJane aims to advance the conversation around novel vaccine platforms and their role in respiratory disease prevention, seeking to drive future vaccine innovations.